Tag: Ionis Pharmaceuticals
GSK advances in Hepatitis B cure with FDA’s fast track for bepirovirsen
In a significant development for the treatment of chronic hepatitis B (CHB), GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration ... Read More
AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN
In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration (FDA) has approved Wainua (eplontersen), developed by ... Read More
Ionis Pharmaceuticals begins donidalorsen phase 3 trial in hereditary angioedema
Ionis Pharmaceuticals, a US-based developer of RNA-targeted therapies, has launched the OASIS-HAE phase 3 clinical trial for donidalorsen (formerly IONIS-PKK-LRx) in patients having hereditary angioedema ... Read More
Ionis Pharmaceuticals to take full ownership of Akcea Therapeutics
Ionis Pharmaceuticals is set to take full ownership of Akcea Therapeutics by acquiring the remaining stake of around 24% in the latter for about $500 ... Read More